Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients With Colorectal or Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Patient Participation
Interventions: DRUG: 150 mg of Xeloda®|DRUG: 150 mg of capecitabine
Sponsor: The Affiliated Hospital of Qingdao University